Fredun Pharmaceuticals Delivers Robust FY26 Performance

Fredun Pharmaceuticals Limited (BSE - FREDUN | 539730), one of the leading pharmaceutical formulation manufacturing companies in India, diversified across generics, cosmeceuticals, nutraceuticals, mobility, and animal healthcare products, has reported its audited financial results for Q4 FY26 and FY26.

Performance Highlights & Key Announcement:

- FY26 revenue scales to ₹639 Cr, up 40% YoY, reflecting strong demand traction

- EBITDA jumps 72% YoY to ~₹95 Cr, with margins expanding to 14.8%

- PAT surges ~60% YoY to ₹33 Cr, significantly outpacing revenue growth

- Margins expand across the board, led by operating leverage and cost discipline

- Q4 exits on a strong note, with EBITDA up 67% and PAT up 56% YoY

- Profitability accelerating faster than revenue, indicating improving business quality

- Improved financial ratios and positive cash flow generation, strengthening overall financial health

- Recommended Dividend of ₹0.70 per share recommended by the Board

- Recommended issuance of bonus shares in the ratio of 2:1, i.e. 2 fully paid-up equity shares of ₹10 each for every 1 existing share of ₹10 each, to eligible shareholders/warrant holders as on the record date, subject to shareholder approval.

Commenting on the financial performance Mr. Fredun Medhora, Managing Director, said, "FY26 reflects the steady progress we have made in building a diversified and resilient business. Our growth is coming across segments, with continued strength in generics complemented by increasing traction in nutraceuticals, cosmeceuticals, and pet care. This balanced mix is helping us scale more sustainably and reduce dependence on any single segment. The improvement is clearly visible in our performance, with revenue reaching ₹639 crore and margins strengthening during the year.

At the same time, we have started investing in the next phase of growth. The launch of our premium hormone therapy range and the DAULCÉL platform marks our entry into more specialized, wellness and preventive healthcare segments. These are early steps, but they open up new avenues beyond our traditional business. Alongside this, the expansion of our Palghar facility and the upgrade in our credit rating to IVR BBB+ give us the capacity and financial strength to support future growth.

Going forward, our focus will be on continuing to build across segments while gradually increasing the share of differentiated and higher value products. With multiple growth drivers now in place and a stronger base established, we are confident of sustaining this momentum and delivering consistent growth in the years ahead."

Shares of Fredun Pharmaceuticals Ltd was last trading in BSE at Rs. 2384.10 as compared to the previous close of Rs. 2528.85. The total number of shares traded during the day was 38131 in over 2255 trades.

The stock hit an intraday high of Rs. 2620.00 and intraday low of 2250.00. The net turnover during the day was Rs. 94140496.00.

Source : Equity Bulls

Keywords

FredunPharmaceuticals INE194R01017 Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate